Peroxisome proliferator-activated receptor γ coactivator 1α maintains NAD⁺ bioavailability protecting against steatohepatitis

Abstract

Hepatic metabolic derangements are pivotal incidences in the occurrence of hepatic steatosis, inflammation, and fibrosis. Peroxisome proliferator-activated receptor-γ, coactivator-1α (PGC-1α), a master regulator that mediates adipose metabolism and mitochondrial biogenesis, its role in hepatic steatosis and progression to steatohepatitis remains elusive. By surveying genomic data on nonalcoholic steatohepatitis (NASH) patients available in the Gene Expression Omnibus, we found that PGC-1α was significantly down-regulated compared with healthy controls, implicating the restoration of PGC-1α may ameliorate the hepatopathy. Using a hepatocyte-specific PGC-1α overexpression (LivPGC1α) mouse model, we demonstrated that PGC-1α attenuated hepatic steatosis induced by methionine–choline-deficient diet (MCD). Biochemical measurements and histological examination indicated less inflammatory infiltration, collagen deposition, NF-kB activation, and less lipid accumulation in LivPGC1α liver fed MCD. Further analyses indicated that the NAD⁺-dependent deacetylase sirtuin 2 (SIRT2) interacted with and deacetylated PGC-1α. Congruently, ablation of SIRT2 accelerated the NASH progression in mice fed MCD, while NAD⁺ repletion via its precursor mimicked the beneficial effect of PGC-1α overexpression and was sufficient to alleviate NASH in mice. These findings indicate that hepatic-specific overexpression of PGC-1α exerts a beneficial role in the regulation of steatohepatitis and that pharmacological activation of the SIRT2-PGC-1α-NAD⁺ axis may help to treat NASH.

Keywords

nonalcoholic steatohepatitis / PGC-1α / SIRT2 / NAD ⁺

References

[1] YounossiZM. Non-alcoholic fatty liver disease—a global public health perspective. J Hepatol 2019;70:531–44.

[2] LiJ, ZouB, YeoYH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2019;4:389–98.

[3] CholankerilG, AhmedA. Alcoholic liver disease replaces hepatitis C virus infection as the leading indication for liver transplantation in the United States. Clin Gastroenterol Hepatol 2018;16:1356–8.

[4] FinckBN, KellyDP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest 2006;116:615–22.

[5] LinJ, Handschin C, SpiegelmanBM. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 2005;1: 361–70.

[6] WanX, ZhuX, WangH, et al. PGC1alpha protects against hepatic steatosis and insulin resistance via enhancing IL10-mediated anti-inflammatory response. FASEB J 2020;34:10751–61.

[7] BarrosoWA, Victorino VJ, JeremiasIC, et al. High-fat diet inhibits PGC-1alpha suppressive effect on NFkappaB signaling in hepatocytes. Eur J Nutr 2018;57:1891–900.

[8] Besse-PatinA, Jeromson S, Levesque-DamphousseP, et al. PGC1A regulates the IRS1:IRS2 ratio during fasting to influence hepatic metabolism downstream of insulin. Proc Natl Acad Sci USA 2019;116:4285–90.

[9] Besse-PatinA, Leveille M, OropezaD, et al. Estrogen signals through peroxisome proliferator-activated receptor-gamma coactivator 1alpha to reduce oxidative damage associated with diet-induced fatty liver disease. Gastroenterology 2017;152:243–56.

[10] ArteagaM, ShangN, DingX, et al. Inhibition of SIRT2 suppresses hepatic fibrosis. Am J Physiol Gastrointest Liver Physiol 2016;310:G1155–68.

[11] ColakY, OzturkO, SenatesE, et al. SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Med Sci Monit 2011;17:HY5–9.

[12] KaSO, BangIH, BaeEJ, et al. Hepatocyte-specific sirtuin 6 deletion predisposes to nonalcoholic steatohepatitis by up-regulation of Bach1, an Nrf2 repressor. FASEB J 2017;31:3999–4010.

[13] NassirF, IbdahJA. Sirtuins and nonalcoholic fatty liver disease. World J Gastroenterol 2016;22:10084–92.

[14] RenH, HuF, WangD, et al. Sirtuin 2 prevents liver steatosis and metabolic disorders by deacetylation of hepatocyte nuclear factor 4alpha. Hepatology 2021;74:723–40.

[15] NakagawaT, Guarente L. SnapShot: sirtuins, NAD, and aging. Cell Metab 2014;20:192–92.e191.

[16] KrishnanJ, DanzerC, SimkaT, et al. Dietary obesity-associated Hif1alpha activation in adipocytes restricts fatty acid oxidation and energy expenditure via suppression of the Sirt2-NAD+ system. Genes Dev 2012;26:259–70.

[17] LiDJ, SunSJ, FuJT, et al. NAD(+)-boosting therapy alleviates nonalcoholic fatty liver disease via stimulating a novel exerkine Fndc5/irisin. Theranostics 2021;11:4381–402.

[18] HamaidiI, ZhangL, KimN, et al. Sirt2 inhibition enhances metabolic fitness and effector functions of tumor-reactive T cells. Cell Metab 2020;32:420–36.e12.

[19] VerdinE. NAD(+) in aging, metabolism, and neurodegeneration. Science 2015;350:1208–13.

[20] KatsyubaE, MottisA, ZietakM, et al. De novo NAD(+) synthesis enhances mitochondrial function and improves health. Nature 2018;563:354–9.

[21] BonkowskiMS, Sinclair DA. Slowing ageing by design: the rise of NAD(+) and sirtuin-activating compounds. Nat Rev Mol Cell Biol 2016;17:679–90.

[22] GarianiK, Menzies KJ, RyuD, et al. Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice. Hepatology 2016;63:1190–204.

[23] GarianiK, RyuD, MenziesKJ, et al. Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease. J Hepatol 2017;66:132–41.

[24] MukhopadhyayP, Horvath B, RajeshM, et al. PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis. J Hepatol 2017;66:589–600.

[25] TranMT, Zsengeller ZK, BergAH, et al. PGC1alpha drives NAD biosynthesis linking oxidative metabolism to renal protection. Nature 2016;531:528–32.

[26] HaraN, YamadaK, ShibataT, et al. Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells. J Biol Chem 2007;282:24574–82.

[27] HoutkooperRH, CantoC, WandersRJ, et al. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev 2010;31:194–223.

[28] WilhelmF, Hirrlinger J. The NAD+/NADH redox state in astrocytes: independent control of the NAD+ and NADH content. J Neurosci Res 2011;89:1956–64.

[29] YangH, YangT, BaurJA, et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell 2007;130:1095–107.

[30] SongBJ, AkbarM, AbdelmegeedMA, et al. Mitochondrial dysfunction and tissue injury by alcohol, high fat, nonalcoholic substances and pathological conditions through post-translational protein modifications. Redox Biol 2014;3:109–23.

[31] BaiP, CantoC. The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease. Cell Metab 2012;16:290–5.

[32] ParkMJ, KimDI, LimSK, et al. Thioredoxin-interacting protein mediates hepatic lipogenesis and inflammation via PRMT1 and PGC-1alpha regulation in vitro and in vivo. J Hepatol 2014;61:1151–7.

[33] XuL, HuangZ, LoTH, et al. Hepatic PRMT1 ameliorates diet-induced hepatic steatosis via induction of PGC1alpha. Theranostics 2022;12:2502–18.

[34] ZhaoQ, LiuJ, DengH, et al. Targeting mitochondria-located circRNA SCAR alleviates NASH via reducing mROS output. Cell 2020;183:76–93.e22.

[35] WuL, MoW, FengJ, et al. Astaxanthin attenuates hepatic damage and mitochondrial dysfunction in non-alcoholic fatty liver disease by up-regulating the FGF21/PGC-1alpha pathway. Br J Pharmacol 2020;177:3760–77.

[36] LeveilleM, Besse-Patin A, JouvetN, et al. PGC-1alpha isoforms coordinate to balance hepatic metabolism and apoptosis in inflammatory environments. Mol Metab 2020;34:72–84.

[37] PalikarasK, Tavernarakis N. Mitochondrial homeostasis: the interplay between mitophagy and mitochondrial biogenesis. Exp Gerontol 2014;56:182–88.

[38] EinerC, Hohenester S, WimmerR, et al. Mitochondrial adaptation in steatotic mice. Mitochondrion 2018;40:1–12.

[39] MariM, Caballero F, ColellA, et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab 2006;4:185–98.

[40] WestAP, ShadelGS. Mitochondrial DNA in innate immune responses and inflammatory pathology. Nat Rev Immunol 2017;17:363–75.

[41] BrennerC, Galluzzi L, KeppO, et al. Decoding cell death signals in liver inflammation. J Hepatol 2013;59:583–94.

[42] KoliakiC, Szendroedi J, KaulK, et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab 2015;21:739–46.

[43] NagakawaY, Williams GM, ZhengQ, et al. Oxidative mitochondrial DNA damage and deletion in hepatocytes of rejecting liver allografts in rats: role of TNF-alpha. Hepatology 2005;42:208–15.

[44] WangF, NguyenM, QinFX, et al. SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. Aging Cell 2007;6:505–14.

[45] WatanabeH, InabaY, KimuraK, et al. Sirt2 facilitates hepatic glucose uptake by deacetylating glucokinase regulatory protein. Nat Commun 2018;9:30.

[46] RothgiesserKM, ErenerS, WaibelS, et al. SIRT2 regulates NF-kappaB dependent gene expression through deacetylation of p65 Lys310. J Cell Sci 2010;123:4251–8.

[47] KatsyubaE, AuwerxJ. Modulating NAD(+) metabolism, from bench to bedside. EMBO J 2017;36:2670–683.

[48] YoshinoJ, BaurJA, ImaiSI. NAD(+) intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab 2018;27: 513–28.

[49] HaigisMC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Ann Rev Pathol 2010;5:253–95.

[50] HoutkooperRH, Pirinen E, AuwerxJ. Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol 2012;13:225–38.

[51] ZhuX, ShenW, WangY, et al. Nicotinamide adenine dinucleotide replenishment rescues colon degeneration in aged mice. Signal Transduc Target Ther 2017;2:17017.

[52] WanX, XuC, LinY, et al. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism. J Hepatol 2016;64:925–32.

[53] ZhuX, ShenW, LiuZ, et al. Effect of metformin on cardiac metabolism and longevity in aged female mice. Front Cell Dev Biol 2020;8:626011.

[54] ZhuX, ShenW, YaoK, et al. Fine-tuning of PGC1alpha expression regulates cardiac function and longevity. Circ Res 2019;125: 707–19.

RIGHTS & PERMISSIONS

The Author(s) 2022. Published by Oxford University Press on behalf of Higher Education Press.